Diabetic Foot Ulcer (DFU) Rapid Pathogen Identification
Key facts
- Who runs it
- University of Michigan
- Where
- Ann Arbor, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 44 people enrolled
- Started
- 5 Sept 2024
- Ended
- 18 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Conventional bacterial culture
- Rapid diagnostic group using mNGS technology
- Record updated
- 11 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients with diabetes mellitus
- Have an infected DFU with a surface area ≥0.5 square centimeter (cm2); o DFU Infection status will be clinically recorded at time of enrollment according to Infectious Disease Society of America (IDSA): mild, moderate, or severe infection
- Have a hemoglobin A1c[HbA1c] of 12% or less as measured within the last 6 months,
- Stated willingness to comply with all study procedures and availability for the duration of the study
Who cannot take part
- Bilateral wound or ulcer
- Current infection of Coronavirus disease 2019 (COVID19)
- Uncontrolled blood glucose as demonstrated by a HbA1c of greater than 12%
- Pregnant or lactating
- Unable to provide informed consent or are unwilling to participate
Where in United States
- University of MichiganAnn Arbor, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the role of rapid diagnosis of pathogens in treatment of infection and wound healing in diabetic foot ulcers. This research is studying the use of a new device of people to learn if metagenomic next generation sequencing (mNGS) techniques technology is a feasible tool that can be used to direct targeted antibiotic therapy in infected diabetic foot ulcers.
Read full original descriptionShow less
Participant's tissue will be randomized to usual care tissue collection and cultures (standard of care) or usual care tissue collection and cultures (standard of care) plus metagenomics next generation sequencing (mNGS). The participant's will not be randomized to any treatment (i.e. antibiotic therapy).
The 2 groups in the trial
- Conventional bacterial cultureExisting treatment, for comparison
Wound tissue removed will be sent for standard of care evaluation.
- Conventional bacterial culture plus rapid diagnostic groupTreatment being tested
Wound tissue removed will be sent for standard of care evaluation as well as rapid diagnostic with metagenomics next generation sequencing (mNGS).
Treatment: Conventional bacterial culture and Rapid diagnostic group using mNGS technology
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Role of the Microbiome in Diabetic Foot Ulcers
- Record updated
- 11 March 2026